Ireland· IE-PA-EU/1/18/1279/003-004
AMGLIDIA 6 mg/mL oral suspension
A glibenclamide product containing glibenclamide, registered in Ireland by AMMTek. The same ATC class is registered in 17 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Glibenclamide is registered in 17 of 19 countries.
Countries holding a registration under ATC A10BB01 (glibenclamide), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Glibenclamide · ATC A10BB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of glibenclamide costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.19 in France to $0.82 in Switzerland — a ×4.4 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Glibenclamide · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.82
- IT Italy$0.22
- FR France$0.19
The record
At a glance
HPRA (Ireland)- Active substance
- Glibenclamide
- Manufacturer
- AMMTek
- Country
- Ireland (IE)
- ATC code
- A10BB01
- ATC class
- Glibenclamide
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/18/1279/003-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
767 interactions on record for glibenclamide.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glibenclamide · interactions on record
767 records
- 21 severe
- 472 moderate
- 52 minor
- 222 info
Most severe, free to view
- MiconazoleA07AC01severe
- BosentanC02KX01severe
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glibenclamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAMGLIDIAAMMTeK, Paris
- SpainAMGLIDIA 6 mg/ml SUSPENSION ORALAmmtek
- FinlandAMGLIDIAAMMTek
- FranceAMGLIDIA 6 mg/mL, suspension buvableAMMTEK
- IcelandAMGLIDIAAMMTek
- NetherlandsAMGLIDIA 6 mg/ml orale suspensieAMMTeK
- PolandAmglidiaAMMTeK
- BelgiumAmglidia 6 mg/mlAMMTeK
Authorised across Europe · EMA
The same active substance is authorised in 13 EEA countries. Names it is sold under:
- Cyprus · Glibesyn, Glitisol
- Germany · Glib-Ratiopharm S, Glibenclamid Abz
- Spain · Glucolón
- France · Daonil, Glibenclamide Arrow
- United Kingdom (Northern Ireland) · Glibenclamide Activase Pharmaceuticals, Glibenclamide Ennogen Ip
- Greece · Asugrin, Deroctyl
- Iceland · Amglidia
- Italy · Gliben, Gliboral
- Liechtenstein · Amglidia
- Malta · Glitisol
- Norway · Amglidia
- Portugal · Glibenclamida Generis
- Romania · Glibenclamidă Arena
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f90920b8-1726-448d-a5ea-77d715e8a209 GET /v1/drugs/f90920b8-1726-448d-a5ea-77d715e8a209?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral suspension",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A10BB",
"A10BB01"
],
"strength": null,
"pa_number": "EU/1/18/1279/003-004",
"substances": [
"Glibenclamide"
],
"legal_basis": "Hybrid application (Article 10(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "24/05/2018",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about glibenclamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.